Eric Legangneux
Basel, BS, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
A Pooled Analysis of Three Randomized Phase I/IIa Clinical Trials Confirms Absence of a Clinically Relevant Effect on the QTc Interval by Umibecestat.
Journal: Clinical and translational science
Published: February 25, 2020
Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Intravenous Siponimod: A Randomized, Open-label Study in Healthy Subjects.
Journal: Clinical therapeutics
Published: August 16, 2019
Effect of Fluconazole Coadministration and CYP2C9 Genetic Polymorphism on Siponimod Pharmacokinetics in Healthy Subjects.
Journal: Clinical pharmacokinetics
Published: August 09, 2018
Siponimod pharmacokinetics, safety, and tolerability in combination with rifampin, a CYP2C9/3A4 inducer, in healthy subjects.
Journal: European journal of clinical pharmacology
Published: May 22, 2018
Metabolism and Disposition of Siponimod, a Novel Selective S1P1/S1P5 Agonist, in Healthy Volunteers and In Vitro Identification of Human Cytochrome P450 Enzymes Involved in Its Oxidative Metabolism.
Journal: Drug metabolism and disposition: the biological fate of chemicals
Published: November 20, 2017
Impact of siponimod on vaccination response in a randomized, placebo-controlled study.
Journal: Neurology(R) neuroimmunology & neuroinflammation
Published: March 11, 2017
Pharmacokinetics, safety, and tolerability of siponimod (BAF312) in subjects with severe renal impairment: A single-dose, open-label, parallel-group study .
Journal: International journal of clinical pharmacology and therapeutics
Published: November 15, 2016
Pharmacokinetics, safety, and tolerability of siponimod (BAF312) in subjects with different levels of hepatic impairment: a single-dose, open-label, parallel-group study .
Journal: International journal of clinical pharmacology and therapeutics
Published: July 23, 2016
Intravenous Dosing as an Alternate Approach to Safely Achieve Supratherapeutic Exposure for Assessments of Cardiac Repolarization: A Randomized Clinical Trial with Mavoglurant (AFQ056).
Journal: Clinical therapeutics
Published: June 24, 2016
Pharmacokinetic and pharmacodynamic interaction of siponimod (BAF312) and propranolol in healthy subjects.
Journal: International journal of clinical pharmacology and therapeutics
Published: August 27, 2015
Effect of mavoglurant (AFQ056), a selective mGluR5 antagonist, on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and levonorgestrel in healthy women.
Journal: International journal of clinical pharmacology and therapeutics
Published: May 07, 2015
Last Updated: 09/26/2026